Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-therapeutic design platform Posted on 11. April 2023
Vernalis Research and Contera Pharma A/S announce a strategic collaboration Posted on 27. September 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation Posted on 8. September 2022
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology Posted on 7. July 2021
Contera Pharma, subsidiary of Bukwang, raises 51 billion KRW in Series B financing round Posted on 22. July 2020